Janssen COVID-19 Vaccine
E49854
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
Observed surface forms (1)
| Surface form | As subject | As object |
|---|---|---|
| Johnson & Johnson COVID-19 Vaccine | 0 | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
→
pharmaceutical product → viral vector vaccine → |
| administrationSchedule | single intramuscular injection of 0.5 mL → |
| administrationSite | deltoid muscle → |
| ageGroupIndication | adults 18 years and older → |
| alsoKnownAs |
Ad26.COV2.S
→
Janssen COVID-19 Vaccine →
surface form:
Johnson & Johnson COVID-19 Vaccine
|
| antigen | SARS-CoV-2 spike protein → |
| ATCCode | J07BX03 → |
| belongsToCompany | Johnson & Johnson → |
| brandOwner | Janssen Pharmaceuticals → |
| clinicalTrialPhase3 | ENSEMBLE trial → |
| commonAdverseReactions |
fatigue
→
headache → injection site pain → myalgia → nausea → |
| contraindication |
known severe allergy to a component of the vaccine
→
severe allergic reaction to a previous dose → |
| countryOfFirstAuthorization |
United States of America
→
surface form:
United States
|
| dateOfFirstAuthorization | 2021-02-27 → |
| developer |
Janssen Pharmaceuticals
→
Johnson & Johnson → |
| doesNotRequire | ultra-cold storage → |
| doseRegimen | single dose → |
| efficacyAgainstSevereCOVID19 | higher than efficacy against moderate disease → |
| efficacyAgainstSymptomaticCOVID19 | approximately 66 percent in global phase 3 trial → |
| indication | prevention of COVID-19 in humans → |
| manufacturer |
Janssen Pharmaceuticals
→
Johnson & Johnson → |
| pharmaceuticalForm | suspension for injection → |
| rareAdverseEvents |
Guillain–Barré syndrome
→
thrombosis with thrombocytopenia syndrome → |
| regulatoryAgency |
Food and Drug Administration
→
surface form:
U.S. Food and Drug Administration
|
| regulatoryStatusChange | use restricted in some countries due to safety concerns → |
| regulatorySubmissionType | Emergency Use Authorization → |
| routeOfAdministration | intramuscular injection → |
| storageRequirement | refrigeration → |
| storageTemperature | 2–8 °C → |
| targetDisease |
COVID-19 vaccines
→
surface form:
COVID-19
|
| targetVirus |
COVID-19 vaccines
→
surface form:
SARS-CoV-2
|
| technologyPlatform | Ad26 vector platform → |
| trialSponsor | Janssen Pharmaceuticals → |
| usesViralVector | human adenovirus serotype 26 (Ad26) → |
| vaccineType | non-replicating viral vector vaccine → |
| worldHealthOrganizationEULDate | 2021-03-12 → |
| worldHealthOrganizationStatus | Emergency Use Listing granted → |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Johnson & Johnson COVID-19 Vaccine